Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $8.20 Consensus Price Target from Brokerages

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has earned a consensus recommendation of “Reduce” from the twelve ratings firms that are currently covering the firm, MarketBeat.com reports. Four investment analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $8.20.

FULC has been the topic of a number of recent analyst reports. Citigroup lowered shares of Fulcrum Therapeutics from an “underperform” rating to an “underweight” rating in a report on Tuesday, June 2nd. Piper Sandler lowered shares of Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating and set a $3.00 price target on the stock. in a report on Tuesday, June 2nd. Stifel Nicolaus lowered shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $3.00 price target on the stock. in a report on Tuesday, June 2nd. HC Wainwright lowered shares of Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and set a $3.00 price target on the stock. in a report on Tuesday, June 2nd. Finally, Jefferies Financial Group set a $4.00 price target on shares of Fulcrum Therapeutics in a report on Tuesday, June 2nd.

Institutional Investors Weigh In On Fulcrum Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Suvretta Capital Management LLC lifted its position in Fulcrum Therapeutics by 21.9% in the 4th quarter. Suvretta Capital Management LLC now owns 6,561,111 shares of the company’s stock worth $74,206,000 after buying an additional 1,180,111 shares in the last quarter. Nantahala Capital Management LLC lifted its position in Fulcrum Therapeutics by 8.9% in the 3rd quarter. Nantahala Capital Management LLC now owns 4,670,784 shares of the company’s stock worth $42,971,000 after buying an additional 382,485 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its position in Fulcrum Therapeutics by 53.0% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,589,000 shares of the company’s stock worth $31,572,000 after buying an additional 1,589,000 shares in the last quarter. Braidwell LP lifted its position in Fulcrum Therapeutics by 1,294.7% in the 4th quarter. Braidwell LP now owns 3,061,222 shares of the company’s stock worth $34,622,000 after buying an additional 2,841,734 shares in the last quarter. Finally, Siren L.L.C. lifted its position in Fulcrum Therapeutics by 20.5% in the 1st quarter. Siren L.L.C. now owns 2,350,000 shares of the company’s stock worth $18,024,000 after buying an additional 400,000 shares in the last quarter. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Price Performance

FULC stock opened at $3.76 on Thursday. Fulcrum Therapeutics has a 52-week low of $2.83 and a 52-week high of $15.74. The company’s 50 day simple moving average is $5.92 and its 200-day simple moving average is $8.43. The firm has a market capitalization of $250.53 million, a P/E ratio of -3.27 and a beta of 2.93.

Fulcrum Therapeutics (NASDAQ:FULC) last released its quarterly earnings results on Monday, April 27th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.06. Sell-side analysts predict that Fulcrum Therapeutics will post -0.67 EPS for the current fiscal year.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.